Therapeutic targeting the loss of the Birt-Hogg-Dubé suppressor gene

Molecular Cancer Therapeutics

Volumn 10, Issue 1, 2011, Pages 80-89

  Lu, Xiaohong ^a   Wei, Wenbin ^b   Fenton, Janine ^a   Nahorski, Michael S ^a   Rabai, Erzsebet ^a   Reiman, Anne ^a   Seabra, Laurence ^a   Nagy, Zsuzsanna ^a   Latif, Farida ^a,b   Maher, Eamonn R ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' (3 CYANOMORPHOLINO) 3' DEAMINODOXORUBICIN; 3' DEAMINO 3' MORPHOLINODOXORUBICIN; ANTINEOPLASTIC AGENT; BISANTRENE; BRUCEANTIN; CASPASE 3; CASPASE 7; CHROMOMYCIN A3; DIDEMNIN B; DOXORUBICIN; ECHINOMYCIN; MENOGARIL; MITHRAMYCIN; N,N DIBENZYLDAUNOMYCIN; NSC 13502; NSC 226080; NSC 266492; NSC 268242; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHYLLANTHOSIDE; PROTEIN FOLLICULIN; PROTEIN P53; RAPAMYCIN; TENIPOSIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

AMINO ACID SUBSTITUTION; ARTICLE; BIRT HOGG DUBE SYNDROME; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CODON; CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PLICAMYCIN; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TUMOR SUPPRESSOR PROTEINS;

EID: 78751523009     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0628     Document Type: Article

References (26)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
2. Foster K, Prowse A, Van Den Berg A, Fleming S, Hulsbeek MM, Crossey PA, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Human molecular genetics 1994;3:2169-73.
3. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes, chromosomes & cancer 1998;22:200-9.
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
5. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66:2000-11.
6. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20.
7. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clinical genitourinary cancer 2009;7:28-33.
8. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke C, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008;45:321-31.
9. Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, Ungari S, et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 2009;10:1199-206.
10. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002;2:157-64.
11. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 2005;76:1023-33.
12. Lim DH, Rehal PK, Nahorski MS, Macdonald F, Claessens T, Van Geel M, et al. A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Human mutation 2009;31: E1043-51.
13. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006;103:15552-7.
14. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 2008;415:60-7.
15. Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, et al. Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. Oncogene 2008;27:5339-47.
16. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008;100:140-54.
17. Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PloS One 2008;3:e3581.
18. Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clinical genitourinary cancer 2008;6Suppl 1:S7-13.
19. Yang Y, Padilla-Nash HM, Vira MA, Abu-Asab MS, Val D, Worrell R, et al. The U.K.257 cell line: a novel model for studies of the human Birt-Hogg-Dube gene pathway. Cancer genetics and cytogenetics 2008;180:100-9.
20. Lu X, Errington J, Chen VJ, Curtin NJ, Boddy AV, Newell DR. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 2000;6:271-7. (Pubitemid 30065002)
21. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
22. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24: 227-35.
23. Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 2007;67:5896-905.
24. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007; 110:2682-90.
25. Bataller M, Mendez C, Salas JA, Portugal J. Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells. Mol Cancer Ther 2008;7:2988-97.
26. Kim CM, Vocke C, Torres-Cabala C, Yang Y, Schmidt L, Walther M, et al. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors. J Urol 2006;175:1908-14.